株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

MRSA(メチシリン耐性黄色ブドウ球菌)薬剤の将来動向

MRSA Drug Futures

発行 Espicom Business Intelligence 商品コード 133798
出版日 ページ情報 英文 108 Pages
納期: 即日から翌営業日
価格
こちらの商品の販売は終了いたしました。
Back to Top
MRSA(メチシリン耐性黄色ブドウ球菌)薬剤の将来動向 MRSA Drug Futures
出版日: 2010年09月03日 ページ情報: 英文 108 Pages

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

2011年以降、MRSA(メチシリン耐性黄色ブドウ球菌)に上市予定の3つの薬剤は同市場に11億米ドルを追加し、同市場は41億米ドルを超える規模になるとみられています。

当レポートでは、MRSAの概要と上市済みおよび第3相薬剤による今後5年間の売上予測、第2相段階にある有望薬剤の評価などをまとめ、概略下記の構成でお届けいたします。

エグゼクティブサマリー

MRSA(メチシリン耐性黄色ブドウ球菌)の概要

  • 細菌
  • 遺伝子
  • MRSA感染
    • MRSA感染はどのように広がるのか
    • 市中感染と院内感染
  • 抗生物質への耐性
    • なぜ耐性が問題となっているのか
  • 患者統計
    • 米国
    • 欧州
  • 現在の備蓄
  • 治療ガイドライン
    • 臨床治療戦略
    • 細菌学戦略
  • 処方習慣の変更
  • 抗生物質開発への投資の取組み
  • 結論

2016年までの世界の売上予測

競合率分析

認可薬剤

  • Ceftobiprole
  • Daptomycin
  • Fusidic acid
  • Linezolid
  • Teicoplanin
  • Telavancin
  • Tigecycline
  • Vancomycin

第3相薬剤

  • Ceftaroline
  • Dalbavancin
  • Oritavancin
  • PT K 0796

第2/3相薬剤

  • Torezolid

第2層薬剤

  • BC-3781
  • Delafloxacin
  • Iclaprim
  • PT Z601
  • TD-1792

付録

図表

目次
Product Code: 3937

Abstract

Summary

This new 105+ page August 2010 report provides a complete briefing on MRSA and the companies, products and research that are shaping the sector' s future.

Category: Pharmaceuticals, Healthcare, Drug prospects, therapeutics

META Description

MRSA: a complex issue

MRSA infection - especially the hospital acquired variety - has been front page news for some years, but reports of falling rates of infection in the US and Europe masks the real situation as far as drug treatments are concerned. Changes to clinical practice and attitudes to hygiene have played a significant part in reducing the incidence of MRSA. There remains the unresolved, but improving issue of the inappropriate over prescription of antibiotics and the resulting growth in resistance to many front line therapies. Despite progress, the fact remains that the arsenal of drugs available to treat MRSA remains limited.

Current therapies and future approaches

It' s not all bad news. A number of drugs with different mechanisms of action have been approved for the treatment of infections caused by MRSA and there is a mixture of antibiotic classes in development for MRSA, including older ones, such as glycopeptides, modified versions of older classes, such as neoglycosides, and combinations, such as heterodimers (betalactam+glycopeptide).

The problem of ever-evolving resistance remains, and it is only a matter of time before the resourceful bacteria evolve once again to become resistant to novel antibiotic classes. It is in this regard that perhaps immunotherapies and vaccines may be the real key to success against MRSA.

The future MRSA landscape

Three new products expected to launch from 2011 will add US$1.1 billion to the sector' s value taking the total MRSA market to in excess of US$4.1 billion. Pfizer will continue to dominate but its percentage share will diminish: declining revenues from Zyvox will be offset by increasing sales of Tygacil which will result in a small decline in overall revenues. At the same time Cubist Pharmaceuticals' Cubicin and LEO Pharma' s Fucidin are expected to show strong growth, the former becoming the most valuable product for treating MRSA with almost blockbuster sales of US$911 million in 2016.

Of the new products expected to launch, Paratek Pharmaceuticals/Novartis' PTK 0796 has an 80% chance of reaching the market, largely due to the drug' s advantageous mode of action and proof of concept and is forecast to achieve sales of US$454 million by 2016.

Squaring the circle?

The inherent commercial problems of developing an antibiotic which, by its nature, could be redundant in a short amount of time has not encouraged a great deal of the industry' s R&D spend to be invested in this area. However the spectre of ever mutating MRSA (and similar) pathogens leading to the uncontrolled spread of infection is possible. Pharma - and government - need to invest more in antibiotic R&D with the aim of developing drugs that work in new ways to attempt to avoid resistance development. In the US, the Infectious Diseases Society of America has suggested a number of incentives related to IP protection, tax breaks and funding to encourage industry to tackle more effectively this critical area.

This new 105+ page August 2010 report provides a complete briefing on MRSA and the companies, products and research that are shaping the sectors future More Information...

The benefits of this report:

  • A comprehensive review of MRSA putting the pathogen into its research and clinical context
  • Original analysis and 5-year sales forecasting for 11 launched and Phase III products
  • An assessment of 5 promising Phase II pipeline prospects
  • Novel, critical evaluation and scoring of each product

With this report you can...

  • Understand the role of staphylococcus aureus
  • Know the differing risk factors of HA-MRSA and CA-MRSA
  • Know how MRSA manifests itself
  • Understand how bacterial mutation occurs and resistance develops
  • Evaluate trends in US prevalence of MRSA and assess which European countries have the highest/lowest incidence rates
  • Understand the arguments around research funding and the incentives for the industry which are proposed in the US
  • Review current product offerings: there are 8 products from 7 companies - what are they?

Questions answered...

  • What development hurdles must Basilia overcome with Zeftera?
  • What clinical advantages does Cubist' s Cubicin has over its competitors?
  • To what degree will Pfizer' s Zyvox be affected by generic competition in 2015?
  • What are the prospects and challenges for Forest' s new

Therapeutic approaches

  • Beta-lactum
  • Glycopeptides
  • Macrolides
  • Streptogramins
  • Aminoglycosides

Table of Contents

EXECUTIVE SUMMARY

MRSA OVERVIEW

  • Bacteria
    • Staphylococcus aureus
  • Genetics
  • MRSA Infection
    • How Does MRSA Infection Typically Manifest?
    • Community-acquired Versus Hospital-acquired MRSA
  • How Does Resistance to Antibiotics Develop?
    • Why is Resistance Now Such a Problem?
  • Patient Statistics
    • MRSA in the US
    • MRSA in Europe
  • Wh at' s in the Current Arsenal?
  • Treatment Guidelines
    • The Clinical Treatment Strategy
    • The Bacteriologic Strategy
  • Changing Prescribing Habits
    • Incentives for Pharma to Invest in Antibiotic Development
    • Conclusions

GLOBAL SALES FORECASTS TO 2016

COMPETITOR RATIO ANALYSIS

APPROVED PRODUCTS

  • Ceftobiprole
    • Mode of Action
    • Current Status
    • Proof of Concept/Clinical Data
    • Development Risks
    • Company Expertise
    • Competition within the Market-place
    • Competitor Ratio Analysis
    • Forecast
    • Clinical Trial Results
  • Daptomycin
    • Mode of Action
    • Current Status
    • Proof of Concept/Clinical Data
    • Company Expertise
    • Competition within the Market-place
    • Patent Expiry
    • Generic Competition
    • Competitor Ratio Analysis
    • Forecast
    • Clinical Trial Results
  • Fusidic acid
    • Mode of Action
    • Current Status
    • Proof of Concept/Clinical Data
    • Development Risks
    • Company Expertise
    • Competition within the Market-place
    • Competitor Ratio Analysis
    • Forecast
    • Clinical Trial Results
  • Linezolid
    • Mode of Action
    • Current Status
    • Proof of Concept/Clinical Data
    • Development Risks
    • Company Expertise
    • Competition within the Market-place
    • Patent Expiry
    • Generic Competition
    • Competitor Ratio Analysis
    • Forecast
    • Clinical Trial Results
  • Teicoplanin
    • Mode of Action
    • Current Status
    • Proof of Concept/Clinical Data
    • Development Risks
    • Company Expertise
    • Competition within the Market-place
    • Generic Competition
    • Competitor Ratio Analysis
    • Forecast
    • Clinical Trial Results
  • Telavancin
    • Mode of Action
    • Current Status
    • Proof of Concept/Clinical Data
    • Development Risks
    • Company Expertise
    • Competition within the Market-place
    • Data Exclusivity
    • Patent Expiry
    • Competitor Ratio Analysis
    • Forecast
    • Clinical Trial Results
  • Tigecycline
    • Mode of Action
    • Current Status
    • Proof of Concept/Clinical Data
    • Development Risks
    • Company Expertise
    • Competition within the Market-place
    • Data Exclusivity
    • Patent Expiry
    • Generic Competition
    • Competitor Ratio Analysis
    • Forecast
    • Clinical Trial Results
  • Vancomycin
    • Mode of Action
    • Current Status
    • Development Risks
    • Company Expertise
    • Competition within the Market-place
    • Generic Competition
    • Competitor Ratio Analysis
    • Forecast

PHASE III PRODUCTS

  • Ceftaroline
    • Mode of Action
    • Current Status
    • Proof of Concept/Clinical Data
    • Development Risks
    • Company Expertise
    • Competition within the Market-place
    • Competitor Ratio Analysis
    • Forecast
    • Clinical Trial Results
  • Dalbavancin
    • Mode of Action
    • Current Status
    • Proof of Concept/Clinical Data
    • Development Risks
    • Company Expertise
    • Competition within the Market-place
    • Competitor Ratio Analysis
    • Clinical Trial Results
  • Oritavancin
    • Mode of Action
    • Current Status
    • Proof of Concept/Clinical Data
    • Development Risks
    • Company Expertise
    • Competition within the Market-place
    • Competitor Ratio Analysis
    • Clinical Trial Results
  • PTK 0796
    • Mode of Action
    • Current Status
    • Proof of Concept/Clinical Data
    • Development Risks
    • Company Expertise
    • Competition within the Market-place
    • Competitor Ratio Analysis
    • Forecast
    • Clinical Trial Results

PHASE II/III PRODUCTS

  • Torezolid
    • Mode of Action
    • Current Status
    • Proof of Concept/Clinical Data
    • Development Risks
    • Company Expertise
    • Competition Within the Market-place
    • Competitor Ratio Analysis
    • Forecast
    • Clinical Trial Results

PHASE II PRODUCTS

  • BC-3781
    • Mode of Action
    • Current Status
    • Proof of Concept/Clinical Data
    • Development Risks
    • Company Expertise
    • Competition within the Market-place
    • Competitor Ratio Analysis
    • Clinical Trial Results
  • Delafloxacin
    • Mode of Action
    • Current Status
    • Proof of Concept/Clinical Data
    • Development Risks
    • Company Expertise
    • Competition within the Market-place
    • Competitor Ratio Analysis
    • Clinical Trial Results
  • Iclaprim
    • Mode of Action
    • Current Status
    • Proof of Concept/Clinical Data
    • Development Risks
    • Company Expertise
    • Competition in the Market-place
    • Competitor Ratio Analysis
    • Clinical Trial Results
  • PT Z601
    • Mode of Action
    • Current Status
    • Proof of Concept/Clinical Data
    • Development Risks
    • Company Expertise
    • Competition within the Market-place
    • Competitor Ratio Analysis
    • Clinical Trial Results
  • TD-1792
    • Mode of Action
    • Current Status
    • Proof of Concept/Clinical Data
    • Development Risks
    • Company Expertise
    • Competition within the Market-place
    • Competitor Ratio Analysis
    • Clinical Trial Results

APPENDIX 1

  • References

APPENDIX 2

  • Bibliography

APPENDIX 3

  • Competitor Ratio Analysis
    • Competitor Ratio Analysis Criteria
    • Competitor Ratio Analysis Score
    • Espicom Drug Monograph Scores in Context

APPENDIX 4

  • Ph ase Transition Probability

LIST OF TABLES

  • Percentage of hVISA Isolates and Corresponding Vancomycin MIC
  • Highest and Lowest Values of Methicillin-Resistant Isolates in Europe in 2008
  • Summary of the Main Antibiotics and their Mechanisms of Action
  • Summary of Mutations found in S. aureus with Daptomycin MICs Above the Susceptible Range
  • Drugs Approved for the Treatment of MRSA Infections
  • Drugs in Development to Treat MRSA
  • CDC Steps to Aid in Prevention of Antimicrobial Resistance
  • Sales Forecasts of Current and Future Leading MRSA Drugs (US$ millions)
  • Summary of Competitor Ratio Analysis Scores
  • Zeftera Sales (2009-2016)
  • Cubist' s Sales of Cubicin by Indication (2008-2016)
  • Fucidin Sales (2008-2016)
  • Linezolid Sales by Region (2009-2016)
  • Cure Rates for the ITT Population with Confirmed Enterococcal Disease
  • Clinical Cure Rate for ME Linezolid-treated Patients
  • Results at Test-of-cure Visit
  • Test-of-cure Cure Rates for ME Patients with DFIs
  • Astellas' Targocid Sales (2008-2016)
  • Vibativ Sales (2009-2016)
  • Tygacil Sales (2008-2016)
  • Vancomycin Sales by Company (2008-2016)
  • Ceftaroline Sales (2011-2016)
  • First Follow-up Visit Results from ARRD
  • First Follow-up Visit in the ARRI Study
  • PTK 0796 Sales (2013-2016)
  • Torezolid Sales (2013-2016)
  • Summary of ASSIST-1 and ASSIST-2 Data
  • Probability of Launch

LIST OF FIGURES & CHARTS

  • Typical Structures Contained within Gram-positive and -negative Bacteria
  • Staphylococcus aureus
  • The Three Main Methods of Genetic Information Exchange for Bacteria
  • Number of Invasive MRSA Cases and Deaths
  • Proportion of S. aureus Bacteria Shown to be Methicillin Resistant in Each Country
  • Relationship Between the Percentage of Methicillin-Resistant Bacteria and Antibiotic Consumption
  • Antibiotic Targets in the Bacterium
  • Predicted Sales Figures for Launched MRSA Products
  • Predicted Sales Figures for Phase III MRSA Products
  • Chemical Structure of Ceftobiprole
  • Zeftera Sales (2009-2016)
  • Chemical Structure of Daptomycin
  • Cubist' s Sales of Cubicin (2008-2016)
  • Chemical Structure of Sodium Fusidate
  • Fucidin Sales (2008-2016)
  • Chemical Structure of Linezolid
  • Zyvox Sales (2008-2016)
  • Astellas' Targocid Sales (2008-2016)
  • Chemical Structure of Telavancin
  • Vibativ Sales (2009-2016)
  • Chemical Structure of Tigecycline
  • Tygacil Sales (2008-2016)
  • Chemical Structure of Vancomycin
  • Vancomycin Sales by Company (2008-2016)
  • Chemical Structure of Ceftaroline
  • Ceftaroline Sales (2011-2016)
  • Chemical Structure of Dalbavancin
  • Chemical Structure of Oritavancin
  • PTK 0796 Sales (2013-2016)
  • Chemical Structure of Torezolid
  • Torezolid Sales (2008-2016)
Back to Top